Tumor Necrosis Factor α–Induced Protein 8–Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta–Activated Kinase 1 Activation

NAFLD prevalence has increased rapidly and become a major global health problem. Tumor necrosis factor α–induced protein 8–like 2 (TIPE2) plays a protective role in a cluster of liver diseases, such as autoimmune hepatitis, hepatitis B, and hepatocellular carcinoma. However, the function of TIPE2 in NAFLD remains unknown. Here, we investigated the role of TIPE2 in the development of NAFLD.

[1]  Haibo Xu,et al.  TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. , 2020, Cell metabolism.

[2]  Wen Zhang,et al.  The SCFβ-TrCP E3 Ubiquitin Ligase Regulates Immune Receptor Signaling by Targeting the Negative Regulatory Protein TIPE2 , 2020, The Journal of Immunology.

[3]  Hongliang Li,et al.  Epidemiological Features of NAFLD From 1999 to 2018 in China , 2020, Hepatology.

[4]  Hongliang Li,et al.  Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis , 2019, Hepatology.

[5]  W. Shi,et al.  TIPE2 suppresses Pseudomonas aeruginosa keratitis by inhibiting NF-κB signaling and the infiltration of inflammatory cells. , 2019, The Journal of infectious diseases.

[6]  J. Huard,et al.  TIPE2 gene transfer with adeno-associated virus 9 ameliorates dystrophic pathology in mdx mice. , 2019, Human molecular genetics.

[7]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[8]  Hong Chen,et al.  Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model” , 2018, World journal of gastroenterology.

[9]  A. Yang,et al.  Genome‐wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism , 2018, Molecular immunology.

[10]  Zhi‐Gang She,et al.  Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver , 2018, Hepatology.

[11]  A. McCullough,et al.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. , 2018, Clinics in liver disease.

[12]  M. Trauner,et al.  Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2018, Annual review of pathology.

[13]  Feng Li,et al.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis , 2018, Nature Medicine.

[14]  Cheng Huang,et al.  TIPE2 attenuates liver fibrosis by reversing the activated hepatic stellate cells. , 2017, Biochemical and biophysical research communications.

[15]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[16]  Zhi‐Gang She,et al.  USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity , 2017, Hepatology.

[17]  Wen-Ting Yan,et al.  TIPE2 Inhibits the Expression of Asthma-Related Inflammatory Factors in Hyperstretched Bronchial Epithelial Cells Through the Wnt/β-Catenin Pathway , 2017, Inflammation.

[18]  Jinhua Qian,et al.  Expression and roles of TIPE2 in autoimmune hepatitis , 2017, Experimental and therapeutic medicine.

[19]  Hongliang Li,et al.  The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis , 2016, Hepatology.

[20]  S. Hanazawa,et al.  TIPE2 (Tumor Necrosis Factor α-induced Protein 8-like 2) Is a Novel Negative Regulator of TAK1 Signal* , 2016, The Journal of Biological Chemistry.

[21]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[22]  Hongliang Li,et al.  Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling , 2016, Nature Communications.

[23]  M. Walsh,et al.  Tumor necrosis factor receptor‐ associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system , 2015, Immunological reviews.

[24]  Hongyu Zhang,et al.  TIPE2 acts as a negative regulator linking NOD2 and inflammatory responses in myocardial ischemia/reperfusion injury , 2015, Journal of Molecular Medicine.

[25]  Giulio Marchesini,et al.  Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  Mason R. Mackey,et al.  TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. , 2014, The Journal of clinical investigation.

[27]  Xiaoyan Wang,et al.  Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1 , 2013, Molecular Cancer.

[28]  Xiaoling Liu,et al.  Enhanced Atherosclerosis in TIPE2-Deficient Mice Is Associated with Increased Macrophage Responses to Oxidized Low-Density Lipoprotein , 2013, The Journal of Immunology.

[29]  E. Park,et al.  Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. , 2013, Gastroenterology.

[30]  Xin-yu Liu,et al.  TAK1, more than just innate immunity , 2012, IUBMB life.

[31]  H. Sakurai.  Targeting of TAK1 in inflammatory disorders and cancer. , 2012, Trends in pharmacological sciences.

[32]  G. Zhuang,et al.  TIPE2 Controls Innate Immunity to RNA by Targeting the Phosphatidylinositol 3-Kinase–Rac Pathway , 2012, The Journal of Immunology.

[33]  Wei Guo,et al.  TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection , 2012, Proceedings of the National Academy of Sciences.

[34]  Guido Gerken,et al.  The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.

[35]  Xiao-hong Liang,et al.  Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. , 2011, Molecular immunology.

[36]  Chunhong Ma,et al.  The unique expression profile of human TIPE2 suggests new functions beyond its role in immune regulation. , 2011, Molecular immunology.

[37]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[38]  S. Akira,et al.  Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis , 2009, Proceedings of the National Academy of Sciences.

[39]  Yu-Chen Fan,et al.  Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. , 2009, Clinical immunology.

[40]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[41]  Xiaolu Yang,et al.  TIPE2, a Negative Regulator of Innate and Adaptive Immunity that Maintains Immune Homeostasis , 2008, Cell.

[42]  Y. Zhang,et al.  TIPE2 inhibits TNF-α-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-κB activation. , 2015, International journal of oncology.

[43]  Yigong Shi,et al.  Crystal structure of TIPE2 provides insights into immune homeostasis , 2009, Nature Structural &Molecular Biology.

[44]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .